AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Photocure ASA

Remuneration Information Sep 22, 2025

3714_dirs_2025-09-22_3c0cded4-ad0b-42cb-b8ea-c7d75199506c.html

Remuneration Information

Open in Viewer

Opens in native device viewer

Photocure ASA - Share option grant

Photocure ASA - Share option grant

Oslo, Norway, 22 September 2025 - Photocure ASA (the "Company") (OSE: PHO) has

granted share options to employees.

A total of 348,000 share options, equal to approx. 1.28% of total shares issued

in the Company, were granted to employees at an exercise price at NOK 67.39. The

exercise price is equal to the weighted average share price 30 trading days

before the day of grant with an additional premium of 10% on top of the

calculated average price.

The options are granted in accordance with Photocure's long term incentive

program and the Company's guidelines for remuneration of senior executives, as

approved by Photocure's annual general meeting held on 5 May 2025. The share

option program and properties of the options are further described in the

guidelines.

Of the total grant the following was granted to primary insiders:

·           Dan Schneider, President and Chief Executive Officer, 60,000

options.

·           Erik Dahl, Chief Financial Officer, 35,000 options.

·           Geoffrey Coy, Vice President and General Manager North America,

35,000 options.

·           Anja Gossens-von der Heidt, Head of Global Human Resources, 11,250

options.

In connection with the grant, Photocure cancels 30,000 outstanding options that

expire in the near term. The cancelled options are replaced with options that

are subject to a reset three-year vesting period, fully resetting the vesting

period.

Primary insider notifications pursuant to the market abuse regulation article 19

are attached.

For further information, please contact:

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: [email protected]

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading

Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.